As Drug Shortages Plague The U.S., Could India’s Strides Be Looking To Sell?
This article was originally published in The Pink Sheet Daily
Executive Summary
Aided by an acute drug shortage in the U.S., Agila, the injectables business of Strides, has grown rapidly, sparking speculation of a buyout from a global bidder. PharmAsia News takes a closer look.